{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:44:51Z","timestamp":1792118691097,"version":"4.4.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,3]]},"DOI":"10.7759\/cureus.100719","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T04:23:41Z","timestamp":1767500621000},"source":"Crossref","is-referenced-by-count":4,"title":["Safety Concerns, Mechanistic Pathways, and Knowledge Gaps in the Clinical Use of Selective Serotonin Reuptake Inhibitors"],"prefix":"10.7759","author":[{"given":"Adrian Chin Yan","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.11.1217","article-title":"Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis","volume":"63","author":"Taylor MJ","year":"2006","unstructured":"Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006, 63:1217-23. 10.1001\/archpsyc.63.11.1217","journal-title":"Arch Gen Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1821","article-title":"The discovery of fluoxetine hydrochloride (Prozac)","volume":"4","author":"Wong DT","year":"2005","unstructured":"Wong DT, Perry KW, Bymaster FP. The discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov. 2005, 4:764-74. 10.1038\/nrd1821","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-824315-2.01220-3","article-title":"SSRIs (selective serotonin reuptake inhibitors)","author":"Fain JH","year":"2014","unstructured":"Fain JH, Gad SE. SSRIs (selective serotonin reuptake inhibitors). Encyclopedia of Toxicology.  Elsevier, London, UK; 2014. 8:677-83. 10.1016\/B978-0-12-824315-2.01220-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.01.010","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis","volume":"29","author":"Deng J","year":"2023","unstructured":"Deng J, Rayner D, Ramaraju HB, et al.. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis. Clin Microbiol Infect. 2023, 29:578-86. 10.1016\/j.cmi.2023.01.010","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2021-000017","article-title":"Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis","volume":"1","author":"Johnson CF","year":"2022","unstructured":"Johnson CF, Maxwell M, Williams B, Dougall N, MacGillivray S. Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. BMJ Med. 2022, 1:e000017. 10.1136\/bmjmed-2021-000017","journal-title":"BMJ Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2015-1-66-74","article-title":"Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history","volume":"7","author":"Danilov DS","year":"2015","unstructured":"Danilov DS. Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history. Nevrol nejropsihiatr psihosom. 2015, 7:66-74. 10.14412\/2074-2711-2015-1-66-74","journal-title":"Nevrol nejropsihiatr psihosom"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.2983","article-title":"Efficacy and safety of antidepressants in patients with comorbid depression and medical diseases: an umbrella systematic review and meta-analysis","volume":"80","author":"K\u00f6hler-Forsberg O","year":"2023","unstructured":"K\u00f6hler-Forsberg O, Stiglbauer V, Brasanac J, et al.. Efficacy and safety of antidepressants in patients with comorbid depression and medical diseases: an umbrella systematic review and meta-analysis. JAMA Psychiatry. 2023, 80:1196-207. 10.1001\/jamapsychiatry.2023.2983","journal-title":"JAMA Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-222-9","article-title":"Selective serotonin reuptake inhibitors","author":"Mozayani M","year":"2012","unstructured":"Mozayani M. Selective serotonin reuptake inhibitors. Handbook of Drug Interactions. Mozayani A, Raymon L (ed): Humana Press, Totowa, US; 2012. 215-27. 10.1007\/978-1-61779-222-9"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v05n0402","article-title":"Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care","volume":"5","author":"Pirraglia PA","year":"2003","unstructured":"Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003, 5:153-7. 10.4088\/pcc.v05n0402","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis","volume":"2024","author":"Henssler J","unstructured":"Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024:526-35. 10.1016\/s2215-0366(24)00133-0","journal-title":"Lancet Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/medicines9090045","article-title":"Cutting the first turf to heal post-SSRI sexual dysfunction: a male retrospective cohort study","volume":"9","author":"De Luca R","year":"2022","unstructured":"De Luca R, Bonanno M, Manuli A, Calabr\u00f2 RS. Cutting the first turf to heal post-SSRI sexual dysfunction: a male retrospective cohort study. Medicines (Basel). 2022, 9:45. 10.3390\/medicines9090045","journal-title":"Medicines (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284389","article-title":"Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries","volume":"18","author":"Alabaku O","year":"2023","unstructured":"Alabaku O, Yang A, Tharmarajah S, Suda K, Vigod S, Tadrous M. Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries. PLoS One. 2023, 18:e0284389. 10.1371\/journal.pone.0284389","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199206005-00001","article-title":"Potential indications for the selective serotonin reuptake inhibitors","volume":"6","author":"Boyer WF","year":"1992","unstructured":"Boyer WF. Potential indications for the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1992, 6:5-12. 10.1097\/00004850-199206005-00001","journal-title":"Int Clin Psychopharmacol"},{"key":"ref14","unstructured":"Antidepressant drug consumption per 1,000 people, 2021. (2022). https.\/\/ourworldindata.org\/grapher\/antidepressants-per-capita."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-064245","article-title":"Antidepressant dispensing to US adolescents and young adults: 2016-2022","volume":"153","author":"Chua KP","year":"2024","unstructured":"Chua KP, Volerman A, Zhang J, Hua J, Conti RM. Antidepressant dispensing to US adolescents and young adults: 2016-2022. Pediatrics. 2024, 153:e2023064245. 10.1542\/peds.2023-064245","journal-title":"Pediatrics"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.2432","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis","volume":"74","author":"Locher C","year":"2017","unstructured":"Locher C, Koechlin H, Zion SR, et al.. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry. 2017, 74:1011-20. 10.1001\/jamapsychiatry.2017.2432","journal-title":"JAMA Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v02n0602","article-title":"Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features","volume":"2","author":"Marken PA","year":"2000","unstructured":"Marken PA, Munro JS. Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features. Prim Care Companion J Clin Psychiatry. 2000, 2:205-10. 10.4088\/pcc.v02n0602","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref18","article-title":"High titer (100 g\/L) ethanol production from pretreated corn stover hydrolysate by modified yeast strains","volume":"391","author":"hao R","year":"2024","unstructured":"hao R, Li H, Li Q.. High titer (100 g\/L) ethanol production from pretreated corn stover hydrolysate by modified yeast strains. Bioresour Technol. 2024, 391:129993.","journal-title":"Bioresour Technol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103385","article-title":"Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data","volume":"86","author":"Wang M","year":"2025","unstructured":"Wang M, Chen X, Liu Z, Li Z, Zhu Z, Liu S, Xiao S. Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. EClinicalMedicine. 2025, 86:103385. 10.1016\/j.eclinm.2025.103385","journal-title":"EClinicalMedicine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1644241","article-title":"Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system","volume":"16","author":"Yu Q","year":"2025","unstructured":"Yu Q, Yao J, Li E, et al.. Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system. Front Pharmacol. 2025, 16:1644241. 10.3389\/fphar.2025.1644241","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff AN","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA, et al.. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021, 13:387-401. 10.3390\/neurolint13030038","journal-title":"Neurol Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2023.105672","article-title":"Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): a serotonin reuptake transporter (SERT)-based approach","volume":"173","author":"Sreeja V","year":"2024","unstructured":"Sreeja V, Jose A, Patel S, Menon B, Athira KV, Chakravarty S. Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): a serotonin reuptake transporter (SERT)-based approach. Neurochem Int. 2024, 173:105672. 10.1016\/j.neuint.2023.105672","journal-title":"Neurochem Int"},{"key":"ref23","article-title":"Selective Serotonin Reuptake Inhibitors","author":"Chu A","year":"2023","unstructured":"Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. StatPearls Publishing, Treasure Island (FL), US; 2023."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122744","article-title":"Neuroplasticity and mechanisms of action of acute and chronic treatment with antidepressants in preclinical studies","volume":"12","author":"Rosas-S\u00e1nchez GU","year":"2024","unstructured":"Rosas-S\u00e1nchez GU, Germ\u00e1n-Ponciano LJ, Guillen-Ruiz G, Cueto-Escobedo J, Lim\u00f3n-V\u00e1zquez AK, Rodr\u00edguez-Landa JF, Soria-Fregozo C. Neuroplasticity and mechanisms of action of acute and chronic treatment with antidepressants in preclinical studies. Biomedicines. 2024, 12:2744. 10.3390\/biomedicines12122744","journal-title":"Biomedicines"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.12.001","article-title":"Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment","volume":"23","author":"Crawford AA","year":"2013","unstructured":"Crawford AA, Lewis G, Lewis SJ, Munaf\u00f2 MR. Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment. Eur Neuropsychopharmacol. 2013, 23:1143-50. 10.1016\/j.euroneuro.2012.12.001","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1519-22.2022","article-title":"Selective serotonin reuptake inhibitors within cells: temporal resolution in cytoplasm, endoplasmic reticulum, and membrane","volume":"43","author":"Nichols AL","year":"2023","unstructured":"Nichols AL, Blumenfeld Z, Luebbert L, et al.. Selective serotonin reuptake inhibitors within cells: temporal resolution in cytoplasm, endoplasmic reticulum, and membrane. J Neurosci. 2023, 43:2222-41. 10.1523\/JNEUROSCI.1519-22.2022","journal-title":"J Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11121334","article-title":"Serotonin transporter genetic variation and antidepressant response and tolerability: a systematic review and meta-analysis","volume":"11","author":"Stein K","year":"2021","unstructured":"Stein K, Maruf AA, M\u00fcller DJ, Bishop JR, Bousman CA. Serotonin transporter genetic variation and antidepressant response and tolerability: a systematic review and meta-analysis. J Pers Med. 2021, 11:1334. 10.3390\/jpm11121334","journal-title":"J Pers Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06162-8","article-title":"Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder","volume":"24","author":"Jar\u010du\u0161kov\u00e1 D","year":"2024","unstructured":"Jar\u010du\u0161kov\u00e1 D, Tk\u00e1\u010d I, Hlav\u00e1\u010dov\u00e1 N, et al.. Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder. BMC Psychiatry. 2024, 24:690. 10.1186\/s12888-024-06162-8","journal-title":"BMC Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03356-w","article-title":"Exploring the association between serotonin transporter promoter region methylation levels and depressive symptoms: a systematic review and multi-level meta-analysis","volume":"15","author":"Javelle F","year":"2025","unstructured":"Javelle F, Dao G, Ringleb M, Pulverer W, Bloch W. Exploring the association between serotonin transporter promoter region methylation levels and depressive symptoms: a systematic review and multi-level meta-analysis. Transl Psychiatry. 2025, 15:161. 10.1038\/s41398-025-03356-w","journal-title":"Transl Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852925000161","article-title":"SSRIs: exploring controversies, conundrums, and contentions-epiphenomenon or empirical ingenuity? A comparative panorama for untangling enigma in children and youths","volume":"30","author":"Gupta M","year":"2025","unstructured":"Gupta M, Petti TA. SSRIs: exploring controversies, conundrums, and contentions-epiphenomenon or empirical ingenuity? A comparative panorama for untangling enigma in children and youths. CNS Spectr. 2025, 30:e18. 10.1017\/S1092852925000161","journal-title":"CNS Spectr"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01725-x","article-title":"Antidepressants enter cells, organelles, and membranes","volume":"49","author":"Blumenfeld Z","year":"2024","unstructured":"Blumenfeld Z, Bera K, Castr\u00e9n E, Lester HA. Antidepressants enter cells, organelles, and membranes. Neuropsychopharmacology. 2024, 49:246-61. 10.1038\/s41386-023-01725-x","journal-title":"Neuropsychopharmacology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2023.10.009","article-title":"Serotonin is a common thread linking different classes of antidepressants","volume":"30","author":"Witt CE","year":"2023","unstructured":"Witt CE, Mena S, Holmes J, et al.. Serotonin is a common thread linking different classes of antidepressants. Cell Chem Biol. 2023, 30:1557-70.e6. 10.1016\/j.chembiol.2023.10.009","journal-title":"Cell Chem Biol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2248883","article-title":"Serotonin 5-HT(2B) receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents","volume":"22","author":"McIntyre RS","year":"2023","unstructured":"McIntyre RS. Serotonin 5-HT(2B) receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. Expert Opin Drug Saf. 2023, 22:881-3. 10.1080\/14740338.2023.2248883","journal-title":"Expert Opin Drug Saf"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01178","article-title":"2B determined: the future of the serotonin receptor 2B in drug discovery","volume":"66","author":"Bender AM","year":"2023","unstructured":"Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD. 2B determined: the future of the serotonin receptor 2B in drug discovery. J Med Chem. 2023, 66:11027-39. 10.1021\/acs.jmedchem.3c01178","journal-title":"J Med Chem"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136184","article-title":"Role of serotonin, membrane transporter, and 5-HT2 receptors in pathogenesis of atherosclerotic plaque formation in immature heterozygous low-density lipoprotein-receptor-deficient mice","volume":"26","author":"Sadykova D","year":"2025","unstructured":"Sadykova D, Nigmatullina R, Salakhova K, et al.. Role of serotonin, membrane transporter, and 5-HT2 receptors in pathogenesis of atherosclerotic plaque formation in immature heterozygous low-density lipoprotein-receptor-deficient mice. Int J Mol Sci. 2025, 26:6184. 10.3390\/ijms26136184","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2007.04.001","article-title":"High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [\u00b9\u00b9C]SA4503","volume":"62","author":"Ishikawa M","year":"2007","unstructured":"Ishikawa M, Ishiwata K, Ishii K, et al.. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [\u00b9\u00b9C]SA4503. Biol Psychiatry. 2007, 62:878-83.","journal-title":"Biol Psychiatry"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphs.2014.11.010","article-title":"Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication","volume":"127","author":"Hashimoto K","year":"2015","unstructured":"Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci. 2015, 127:6-9.","journal-title":"J Pharmacol Sci"},{"key":"ref38","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"2012","author":"Ballenger JC","year":"2012","unstructured":"Ballenger JC. Antidepressants and body weight: a comprehensive review and meta-analysis. Yearb Psychiatry Appl Ment Health. 2012, 2012:333-5.","journal-title":"Yearb Psychiatry Appl Ment Health"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21-1310","article-title":"Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials","volume":"106","author":"Guo CM","year":"2022","unstructured":"Guo CM, Harari O, Chernecki C, Thorlund K, Forrest JI. Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials. Am J Trop Med Hyg. 2022, 106:1315-20. 10.4269\/ajtmh.21-1310","journal-title":"Am J Trop Med Hyg"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.5b00033","article-title":"Epigenetic mechanisms of serotonin signaling","volume":"6","author":"Holloway T","year":"2015","unstructured":"Holloway T, Gonz\u00e1lez-Maeso J. Epigenetic mechanisms of serotonin signaling. ACS Chem Neurosci. 2015, 6:1099-109. 10.1021\/acschemneuro.5b00033","journal-title":"ACS Chem Neurosci"},{"key":"ref41","unstructured":"FDA drug safety communication. revised recommendations for Celexa (Citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. (2012). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-recommendations-celexa-c...."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2016.07.165","article-title":"Evaluation of QTc prolongation and dosage effect with citalopram","volume":"6","author":"McClelland J","year":"2016","unstructured":"McClelland J, Mathys M. Evaluation of QTc prolongation and dosage effect with citalopram. Ment Health Clin. 2016, 6:165-70. 10.9740\/mhc.2016.07.165","journal-title":"Ment Health Clin"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010056","article-title":"Off-target effects of antidepressants on vascular function and structure","volume":"10","author":"Dimoula A","year":"2021","unstructured":"Dimoula A, Fotellis D, Aivalioti E, et al.. Off-target effects of antidepressants on vascular function and structure. Biomedicines. 2021, 10:56. 10.3390\/biomedicines10010056","journal-title":"Biomedicines"},{"key":"ref44","article-title":"Fluoxetine","author":"Sohel AJ","year":"2024","unstructured":"Sohel AJ, Shutter MC, Patel P, Molla M. Fluoxetine. StatPearls Publishing, Treasure Island (FL), US; 2024."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199426030-00004","article-title":"Clinical pharmacokinetics of fluoxetine","volume":"26","author":"Altamura AC","year":"1994","unstructured":"Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994, 26:201-14. 10.2165\/00003088-199426030-00004","journal-title":"Clin Pharmacokinet"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks JK","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98:127-34. 10.1002\/cpt.147","journal-title":"Clin Pharmacol Ther"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050711","article-title":"An overview of the systematic reviews about the efficacy of fluvoxamine on depression","volume":"18","author":"Dieckmann LH","year":"2025","unstructured":"Dieckmann LH, Haddad M, Wendt Viola T, Franco Scarante F, Rodrigues da Silva N, Mari JJ. An overview of the systematic reviews about the efficacy of fluvoxamine on depression. Pharmaceuticals. 2025, 18:711. 10.3390\/ph18050711","journal-title":"Pharmaceuticals"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111192","article-title":"Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1\/M2 microglia polarization","volume":"136","author":"Mohamed AF","year":"2025","unstructured":"Mohamed AF, El-Gammal MA, El-Yamany MF, Khodeir AE. Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1\/M2 microglia polarization. Prog Neuropsychopharmacol Biol Psychiatry. 2025, 136:111192. 10.1016\/j.pnpbp.2024.111192","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003886","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy: updated comparisons and meta-analyses of newer versus older trials","volume":"19","author":"Turner EH","year":"2022","unstructured":"Turner EH, Cipriani A, Furukawa TA, Salanti G, de Vries YA. Selective publication of antidepressant trials and its influence on apparent efficacy: updated comparisons and meta-analyses of newer versus older trials. PLoS Med. 2022, 19:e1003886. 10.1371\/journal.pmed.1003886","journal-title":"PLoS Med"},{"key":"ref50","doi-asserted-by":"crossref","DOI":"10.1002\/hup.325","article-title":"A critical review of akathisia, and its possible association with suicidal behaviour","volume":"16","author":"Hansen L","year":"2001","unstructured":"Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol. 2001, 16:495-505.","journal-title":"Hum Psychopharmacol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2161","article-title":"Opportunity for genotype-guided prescribing among adult patients in 11 US health systems","volume":"110","author":"Hicks JK","year":"2021","unstructured":"Hicks JK, El Rouby N, Ong HH, et al.. Opportunity for genotype-guided prescribing among adult patients in 11 US health systems. Clin Pharmacol Ther. 2021, 110:179-88. 10.1002\/cpt.2161","journal-title":"Clin Pharmacol Ther"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2020.1.20190058","article-title":"Prevalence of antidepressant-induced sexual dysfunction among psychiatric outpatients attending a tertiary care hospital","volume":"25","author":"AlBreiki M","year":"2020","unstructured":"AlBreiki M, AlMaqbali M, AlRisi K, AlSinawi H, Al Balushi M, Al Zakwani W. Prevalence of antidepressant-induced sexual dysfunction among psychiatric outpatients attending a tertiary care hospital. Neurosciences (Riyadh). 2020, 25:55-60. 10.17712\/nsj.2020.1.20190058","journal-title":"Neurosciences (Riyadh)"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5480391","article-title":"Cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder","volume":"2016","author":"Sayyah M","year":"2016","unstructured":"Sayyah M, Eslami K, AlaiShehni S, Kouti L. Cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder. Psychiatry J. 2016, 2016:5480391. 10.1155\/2016\/5480391","journal-title":"Psychiatry J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.npbr.2020.03.002","article-title":"Real-world patient experience with sexual dysfunction and antidepressant use in patients with self-reported depression: a cross-sectional survey study","volume":"36","author":"Jacobsen PL","year":"2020","unstructured":"Jacobsen PL, Thorley EM, Curran C. Real-world patient experience with sexual dysfunction and antidepressant use in patients with self-reported depression: a cross-sectional survey study. Neurol Psychiatry Brain Res. 2020, 36:57-64. 10.1016\/j.npbr.2020.03.002","journal-title":"Neurol Psychiatry Brain Res"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2018.54.2.101","article-title":"Addressing the side effects of contemporary antidepressant drugs: a comprehensive review","volume":"54","author":"Wang SM","year":"2018","unstructured":"Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018, 54:101-12. 10.4068\/cmj.2018.54.2.101","journal-title":"Chonnam Med J"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666180605095130","article-title":"Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects","volume":"13","author":"Read J","year":"2018","unstructured":"Read J, Williams J. Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects. Curr Drug Saf. 2018, 13:176-86. 10.2174\/1574886313666180605095130","journal-title":"Curr Drug Saf"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad177","article-title":"Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis","volume":"46","author":"Zhou S","year":"2023","unstructured":"Zhou S, Li P, Lv X, et al.. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023, 46:zsad177. 10.1093\/sleep\/zsad177","journal-title":"Sleep"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01506-5","article-title":"Drug-induced cognitive impairment","volume":"48","author":"Reimers A","year":"2025","unstructured":"Reimers A, Odin P, Ljung H. Drug-induced cognitive impairment. Drug Saf. 2025, 48:339-61. 10.1007\/s40264-024-01506-5","journal-title":"Drug Saf"},{"key":"ref59","article-title":"SSRI-induced indifference","volume":"7","author":"Sansone RA","year":"2010","unstructured":"Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont). 2010, 7:14-8.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib R","year":"2021","unstructured":"Khatib R, Sabir FR, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021, 97:452-8. 10.1136\/postgradmedj-2020-138661","journal-title":"Postgrad Med J"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70004","article-title":"Evaluation of hyponatremia among older adults exposed to selective serotonin reuptake inhibitors and thiazide diuretics","volume":"45","author":"Matsuura T","year":"2025","unstructured":"Matsuura T, Tawfik AG, Ben-Umeh KC, Hansten PD, Malone DC. Evaluation of hyponatremia among older adults exposed to selective serotonin reuptake inhibitors and thiazide diuretics. Pharmacotherapy. 2025, 45:169-76. 10.1002\/phar.70004","journal-title":"Pharmacotherapy"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.880496","article-title":"Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies","volume":"13","author":"Li K","year":"2022","unstructured":"Li K, Zhou G, Xiao Y, Gu J, Chen Q, Xie S, Wu J. Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies. Front Psychiatry. 2022, 13:880496. 10.3389\/fpsyt.2022.880496","journal-title":"Front Psychiatry"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.09.007","article-title":"Drug-induced psychiatric disorders: a pharmacovigilance update","volume":"79","author":"Montastruc F","year":"2024","unstructured":"Montastruc F, Taillefer de Laportaliere T. Drug-induced psychiatric disorders: a pharmacovigilance update. Therapie. 2024, 79:173-9. 10.1016\/j.therap.2023.09.007","journal-title":"Therapie"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1159\/000371865","article-title":"New classification of selective serotonin reuptake inhibitor withdrawal","volume":"84","author":"Chouinard G","year":"2015","unstructured":"Chouinard G, Chouinard VA. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom. 2015, 84:63-71. 10.1159\/000371865","journal-title":"Psychother Psychosom"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050565","article-title":"A focus on abuse\/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIs): analysis of both the European EMA and the US FAERS pharmacovigilance databases","volume":"15","author":"Chiappini S","year":"2022","unstructured":"Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, Schifano F. A focus on abuse\/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIs): analysis of both the European EMA and the US FAERS pharmacovigilance databases. Pharmaceuticals (Basel). 2022, 15:565. 10.3390\/ph15050565","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-180018","article-title":"SSRI and SNRI withdrawal symptoms reported on an internet forum","volume":"29","author":"Stockmann T","year":"2018","unstructured":"Stockmann T, Odegbaro D, Timimi S, Moncrieff J. SSRI and SNRI withdrawal symptoms reported on an internet forum. Int J Risk Saf Med. 2018, 29:175-80. 10.3233\/JRS-180018","journal-title":"Int J Risk Saf Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.08.027","article-title":"A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?","volume":"97","author":"Davies J","year":"2019","unstructured":"Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?. Addict Behav. 2019, 97:111-21. 10.1016\/j.addbeh.2018.08.027","journal-title":"Addict Behav"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S138535","article-title":"Hyponatremia in the elderly: challenges and solutions","volume":"12","author":"Filippatos TD","year":"2017","unstructured":"Filippatos TD, Makri A, Elisaf MS, Liamis G. Hyponatremia in the elderly: challenges and solutions. Clin Interv Aging. 2017, 12:1957-65. 10.2147\/CIA.S138535","journal-title":"Clin Interv Aging"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0338-3","article-title":"Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence","volume":"30","author":"Alwan S","year":"2016","unstructured":"Alwan S, Friedman JM, Chambers C. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. CNS Drugs. 2016, 30:499-515. 10.1007\/s40263-016-0338-3","journal-title":"CNS Drugs"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.73.863.529","article-title":"The syndrome of motor restlessness-a treatable but under-recognised disorder","volume":"73","author":"Bakheit A","year":"1997","unstructured":"Bakheit A. The syndrome of motor restlessness-a treatable but under-recognised disorder. Postgrad Med J. 1997, 73:529-30. 10.1136\/pgmj.73.863.529","journal-title":"Postgrad Med J"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2023-326049","article-title":"Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study","volume":"109","author":"Cornet MC","year":"2024","unstructured":"Cornet MC, Wu YW, Forquer H, et al.. Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study. Arch Dis Child Fetal Neonatal Ed. 2024, 109:294-300. 10.1136\/archdischild-2023-326049","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"ref72","article-title":"Safe use of SSRIs in young adults: how strong is evidence for new suicide warning?","volume":"6","author":"Grunebaum MF","year":"2007","unstructured":"Grunebaum MF, Mann JJ. Safe use of SSRIs in young adults: how strong is evidence for new suicide warning?. Curr Psychiatr. 2007, 6:nihpa81089.","journal-title":"Curr Psychiatr"},{"key":"ref73","unstructured":"Pharmacovigilance. (2025).  https.\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance ."},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1159\/000546109","article-title":"Selective serotonin reuptake inhibitors and risk of serotonin syndrome as consequence of drug-drug interactions: analysis of the FDA Adverse Event Reporting System","volume":"34","author":"Elli C","year":"2025","unstructured":"Elli C, Novella A, Elli C, Pasina L. Selective serotonin reuptake inhibitors and risk of serotonin syndrome as consequence of drug-drug interactions: analysis of the FDA Adverse Event Reporting System. Med Princ Pract. 2025, 34:456-63. 10.1159\/000546109","journal-title":"Med Princ Pract"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00977-1","article-title":"The risk of hyponatremia induced by SSRIs and SNRIs antidepressants: a systematic review and meta-analysis","volume":"26","author":"Li Y","year":"2025","unstructured":"Li Y, Du X, Wu H. The risk of hyponatremia induced by SSRIs and SNRIs antidepressants: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2025, 26:144. 10.1186\/s40360-025-00977-1","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.237","article-title":"The risk of antidepressant-induced hyponatremia: a meta-analysis of antidepressant classes and compounds","volume":"67","author":"Gheysens T","year":"2024","unstructured":"Gheysens T, De Picker L, Van Den Eede F. The risk of antidepressant-induced hyponatremia: a meta-analysis of antidepressant classes and compounds. Eur Psychiatry. 2024, 67:S95. 10.1192\/j.eurpsy.2024.237","journal-title":"Eur Psychiatry"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000847","article-title":"Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review","volume":"32","author":"Mokhtarian A","year":"2025","unstructured":"Mokhtarian A, Siguret V, Jourdi G. Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review. Curr Opin Hematol. 2025, 32:22-33. 10.1097\/MOH.0000000000000847","journal-title":"Curr Opin Hematol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint17070111","article-title":"Selective serotonin reuptake inhibitor-associated intracranial hemorrhage: drug-specific risk patterns and patient-level modifiers","volume":"17","author":"Yayan J","year":"2025","unstructured":"Yayan J, Rasche K. Selective serotonin reuptake inhibitor-associated intracranial hemorrhage: drug-specific risk patterns and patient-level modifiers. Neurol Int. 2025, 17:111. 10.3390\/neurolint17070111","journal-title":"Neurol Int"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000797","article-title":"Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors\/serotonin and noradrenaline reuptake inhibitors","volume":"35","author":"Akgoz I","year":"2024","unstructured":"Akgoz I, Kara H, Ozcelik O, Donmez L, Eryilmaz M, Ozbey G. Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors\/serotonin and noradrenaline reuptake inhibitors. Behav Pharmacol. 2024, 35:460-3. 10.1097\/FBP.0000000000000797","journal-title":"Behav Pharmacol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796024000441.","article-title":"Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence","volume":"18","author":"Healy D","year":"2024","unstructured":"Healy D, Mangin D.\r\n. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sc. 2024, 18:33. 10.1017\/S2045796024000441.","journal-title":"Epidemiol Psychiatr Sc"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01246-4","article-title":"Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database","volume":"45","author":"Gastaldon C","year":"2022","unstructured":"Gastaldon C, Schoretsanitis G, Arzenton E, et al.. Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database. Drug Saf. 2022, 45:1539-49. 10.1007\/s40264-022-01246-4","journal-title":"Drug Saf"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241231116","article-title":"Safety profile of selective serotonin reuptake inhibitors in real-world settings: a pharmacovigilance study based on FDA Adverse Event Reporting System","volume":"58","author":"Zhao Y","year":"2024","unstructured":"Zhao Y, Zhang Y, Yang L, Zhang K, Li S. Safety profile of selective serotonin reuptake inhibitors in real-world settings: a pharmacovigilance study based on FDA Adverse Event Reporting System. Ann Pharmacother. 2024, 58:1105-16. 10.1177\/10600280241231116","journal-title":"Ann Pharmacother"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00630.x","article-title":"Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors","volume":"5","author":"Csoka AB","year":"2008","unstructured":"Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med. 2008, 5:227-33. 10.1111\/j.1743-6109.2007.00630.x","journal-title":"J Sex Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.2.177","article-title":"Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia","volume":"164","author":"Halstead SM","year":"1994","unstructured":"Halstead SM, Barnes TR, Speller JC. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry. 1994, 164:177-83. 10.1192\/bjp.164.2.177","journal-title":"Br J Psychiatry"},{"key":"ref85","article-title":"Antidepressants and suicidal risk","volume":"60","author":"M\u00fcller-Oerlinghausen B","year":"1999","unstructured":"M\u00fcller-Oerlinghausen B, Bergh\u00f6fer A\r\n. Antidepressants and suicidal risk. J Clin Psychiatry\r\n. . 1999, 60:94-9 .","journal-title":"J Clin Psychiatry\r\n."},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman RB","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000, 102:2836-41. 10.1161\/01.cir.102.23.2836","journal-title":"Circulation"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.5152\/npa.2016.12373","article-title":"Metabolic effects of antidepressant treatment [Turkish]","volume":"54","author":"Olguner Eker \u00d6","year":"2017","unstructured":"Olguner Eker \u00d6, \u00d6zsoy S, Eker B, Do\u011fan H. Metabolic effects of antidepressant treatment [Turkish]. Noro Psikiyatr Ars. 2017, 54:49-56. 10.5152\/npa.2016.12373","journal-title":"Noro Psikiyatr Ars"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-022-00845-6","article-title":"Astrocytes in post-traumatic stress disorder","volume":"38","author":"Li B","year":"2022","unstructured":"Li B, Zhang D, Verkhratsky A. Astrocytes in post-traumatic stress disorder. Neurosci Bull. 2022, 38:953-65. 10.1007\/s12264-022-00845-6","journal-title":"Neurosci Bull"},{"key":"ref89","article-title":"Movement Disorders in Psychiatry","author":"Teixeira A","year":"2022","unstructured":"Teixeira A, Stimming EF, Ondo WG. Movement Disorders in Psychiatry. Oxford university press, Oxford, UK; 2022."},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2009.08083","article-title":"Selective serotonin reuptake inhibitor-induced akathisia","volume":"49","author":"Koliscak LP","year":"2009","unstructured":"Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc (2003). 2009, 49:e37-8. 10.1331\/JAPhA.2009.08083","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-426-5","article-title":"Movement Disorders: A Video Atlas","author":"Bhidayasiri R","year":"2012","unstructured":"Bhidayasiri R, Tarsy D. Movement Disorders: A Video Atlas. Humana Press , Totowa, NJ; 2012. 10.1007\/978-1-60327-426-5"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease-it was meant 2B","volume":"132","author":"Hutcheson JD","year":"2011","unstructured":"Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease-it was meant 2B. Pharmacol Ther. 2011, 132:146-57. 10.1016\/j.pharmthera.2011.03.008","journal-title":"Pharmacol Ther"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01676-3","article-title":"Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation","volume":"48","author":"Lagerberg T","year":"2023","unstructured":"Lagerberg T, Matthews AA, Zhu N, Fazel S, Carrero JJ, Chang Z. Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation. Neuropsychopharmacology. 2023, 48:1760-8. 10.1038\/s41386-023-01676-3","journal-title":"Neuropsychopharmacology"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S222888","article-title":"Individual antidepressants and the risk of fractures in older adults: a new user active comparator study","volume":"12","author":"Pisa FE","year":"2020","unstructured":"Pisa FE, Reinold J, Kollhorst B, Haug U, Schink T. Individual antidepressants and the risk of fractures in older adults: a new user active comparator study. Clin Epidemiol. 2020, 12:667-78. 10.2147\/CLEP.S222888","journal-title":"Clin Epidemiol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01359-x","article-title":"Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms","volume":"47","author":"Saggu S","year":"2025","unstructured":"Saggu S, Bai A, Aida M, et al.. Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms. Geroscience. 2025, 47:457-82. 10.1007\/s11357-024-01359-x","journal-title":"Geroscience"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-013-0360-9","article-title":"Recent advances in neuroimaging biomarkers in geriatric psychiatry","volume":"15","author":"Khandai AC","year":"2013","unstructured":"Khandai AC, Aizenstein HJ. Recent advances in neuroimaging biomarkers in geriatric psychiatry. Curr Psychiatry Rep. 2013, 15:360. 10.1007\/s11920-013-0360-9","journal-title":"Curr Psychiatry Rep"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.13004","article-title":"Annual research review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research","volume":"60","author":"Sujan AC","year":"2019","unstructured":"Sujan AC, \u00d6berg AS, Quinn PD, D'Onofrio BM. Annual research review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research. J Child Psychol Psychiatry. 2019, 60:356-76. 10.1111\/jcpp.13004","journal-title":"J Child Psychol Psychiatry"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26071-8","article-title":"Profiling placental DNA methylation associated with maternal SSRI treatment during pregnancy","volume":"12","author":"Inkster AM","year":"2022","unstructured":"Inkster AM, Konwar C, Pe\u00f1aherrera MS, et al.. Profiling placental DNA methylation associated with maternal SSRI treatment during pregnancy. Sci Rep. 2022, 12:22576. 10.1038\/s41598-022-26071-8","journal-title":"Sci Rep"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-024-00753-9","article-title":"Youth suicide crisis: identifying at-risk individuals and prevention strategies","volume":"18","author":"Ajluni V","year":"2024","unstructured":"Ajluni V, Amarasinghe D. Youth suicide crisis: identifying at-risk individuals and prevention strategies. Child Adolesc Psychiatry Ment Health. 2024, 18:58. 10.1186\/s13034-024-00753-9","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.44","article-title":"Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program","volume":"15","author":"Awada Z","year":"2014","unstructured":"Awada Z, Zgheib NK. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program. Pharmacogenomics. 2014, 15:845-56. 10.2217\/pgs.14.44","journal-title":"Pharmacogenomics"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01500-w","article-title":"Identifying major depressive disorder in older adults through naturalistic driving behaviors and machine learning","volume":"8","author":"Chen C","year":"2025","unstructured":"Chen C, Brown DC, Al-Hammadi N, et al.. Identifying major depressive disorder in older adults through naturalistic driving behaviors and machine learning. NPJ Digit Med. 2025, 8:102. 10.1038\/s41746-025-01500-w","journal-title":"NPJ Digit Med"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S495254","article-title":"Pharmacovigilance in action: utilizing VigiBase data to improve clozapine safety","volume":"18","author":"De Las Cuevas C","year":"2024","unstructured":"De Las Cuevas C, Sanz EJ, de Leon J. Pharmacovigilance in action: utilizing VigiBase data to improve clozapine safety. Patient Prefer Adherence. 2024, 18:2261-80. 10.2147\/PPA.S495254","journal-title":"Patient Prefer Adherence"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/421917-safety-concerns-mechanistic-pathways-and-knowledge-gaps-in-the-clinical-use-of-selective-serotonin-reuptake-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T04:23:43Z","timestamp":1767500623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/421917-safety-concerns-mechanistic-pathways-and-knowledge-gaps-in-the-clinical-use-of-selective-serotonin-reuptake-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":102,"URL":"https:\/\/doi.org\/10.7759\/cureus.100719","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,3]]}}}